Traders continue to hunt for good action as the gap narrows between extended big-cap stocks and beat-down smaller names.
Forward earnings estimates dip as the 10-Year Treasury yield rises.
More than the first-quarter revenue miss, the problem was in the company's guidance.
There is a reasonable possibility, in our view, of the recent rally failing near current levels.
Keep in mind earnings are scheduled for Oct. 27 along with a $0.49 dividend on Sept. 30.
Trading action seems to be shifting away from social media-driven names and into stocks with solid fundamentals and charts.
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.
Retests of the lows have been quite rare in recent years.
We will soon see if another V-shape move is in the cards.